LENZ Therapeutics, Inc. (LENZ)
3.20
-0.30
(-8.57%)
USD |
NASDAQ |
Nov 18, 16:00
3.21
+0.01
(+0.31%)
After-Hours: 20:00
LENZ Therapeutics Net Income (Quarterly) : -30.97M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -30.97M |
| June 30, 2026 | -31.92M |
| March 31, 2026 | -41.49M |
| December 31, 2025 | -35.90M |
| September 30, 2025 | -16.70M |
| June 30, 2025 | -14.91M |
| March 31, 2025 | -14.62M |
| December 31, 2024 | -12.65M |
| September 30, 2024 | -10.22M |
| June 30, 2024 | -10.25M |
| March 31, 2024 | -16.65M |
| December 31, 2023 | -23.69M |
| September 30, 2023 | -18.88M |
| June 30, 2023 | -14.73M |
| Date | Value |
|---|---|
| March 31, 2023 | -12.67M |
| December 31, 2022 | -24.60M |
| September 30, 2022 | -24.68M |
| June 30, 2022 | -26.66M |
| March 31, 2022 | -26.14M |
| December 31, 2021 | -18.93M |
| September 30, 2021 | -14.59M |
| June 30, 2021 | -17.53M |
| March 31, 2021 | -19.71M |
| December 31, 2020 | -63.54M |
| September 30, 2020 | -3.384M |
| June 30, 2020 | -1.312M |
| March 31, 2020 | -0.141M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| EyePoint, Inc. | -95.61M |
| Ligand Pharmaceuticals, Inc. | -28.48M |
| Bristol Myers Squibb Co. | 2.162B |
| Context Therapeutics, Inc. | -7.624M |
| Neumora Therapeutics, Inc. | -34.44M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.384M |
| Total Expenses (Quarterly) | 34.35M |
| EPS Diluted (Quarterly) | -0.9856 |
| Enterprise Value | -86.87M |
| Gross Profit Margin (Quarterly) | 86.58% |
| Profit Margin (Quarterly) | -915.2% |
| Earnings Yield | -140.0% |
| Normalized Earnings Yield | -140.05 |